Standout Papers

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line <i>Helicobacter pylori</i> treatment... 2020 2026 2022 2024159
  1. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan (2020)
    Sho Suzuki, Takuji Gotoda et al. Gut

Immediate Impact

23 standout
Sub-graph 1 of 10

Citing Papers

Biomaterials mediated 3R (remove-remodel-repair) strategy: holistic management of Helicobacter pylori infection
2025 Standout
Helicobacter pylori and gastric cancer: mechanisms and new perspectives
2025 Standout
5 intermediate papers

Works of Yohei Ogata being referenced

Kyoto classification risk scoring system and endoscopic grading of gastric intestinal metaplasia for gastric cancer: Multicenter observation study in Japan
2021
Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan
2020 Standout

Author Peers

Author Last Decade Papers Cites
Yohei Ogata 240 145 29 127 29 289
A Qasim 202 116 45 153 18 320
G. M. Gulzar 195 75 24 106 22 304
Adam Harris 210 93 39 147 23 287
R.M. Zagari 280 82 29 187 25 332
Kuniyasu Irie 179 117 28 66 31 255
Bor‐Shyang Sheu 200 58 30 140 16 250
Yoshiki Nomura 165 135 34 70 24 297
Raffaele Salerno 173 121 53 74 27 303
Ilva Daugule 293 115 46 123 32 335
Rongli Cui 223 94 30 59 23 252

All Works

Loading papers...

Rankless by CCL
2026